Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New UK Market Surveillance Levy Could Cost Medtech Companies Millions Each Year

This article was originally published in Clinica

Executive Summary

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) wants to charge an annual fee to manufacturers to pay for its market surveillance activities, but is expected to issue a 12-week public consultation first. The exact level of fee is not yet known but is expected to be in the region of 0.12% of turnover, Mike Kreuzer, regulatory director of the Association of British Healthcare Industries told delegates at the Bristows/ABHI medical device meeting in London on April 21.

You may also be interested in...

Medtech Worried After UK HTA Body Moots Pharma Guidance Fees

The UK health technology assessment body, NICE, has received its first reactions from a medtech industry association to proposals to raise fees from its program of pharma guidance. If, when or how quickly the medtech sector is fully impacted is a matter of concern across the SME-based industry.

EU Regulatory Roundup, November 2020: Plenty Of Advice And Guidance As Deadlines Approach

Those marketing products covered under the EU’s MDR and IVD Regulations have plenty of reading this month to help them prepare. More details have also emerged about the UK’s regulatory future.

Notified Body Pain Points: The Challenges And Obstacles Industry Needs To Avoid

Where are the biggest challenges for notified bodies and manufacturers now there is some experience with the MDR, and can the sector manage the new regulatory requirements successfully?





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts